OCUP - Ocuphire completes enrollment in pediatric patients study of Nyxol eye drops

Ocuphire Pharma (NASDAQ:OCUP) said it completed enrollment in a study, dubbed MIRA-4, evaluating its eye drops Nyxol to reverse pharmacologically-induced mydriasis (RM) in 23 children aged 3-to-11 years old. RM is an unusual dilation or widening of the pupils. The company expects data from the trial in Q2. MIRA-4 is part of a MIRA clinical program. In February, Ocuphire said it had completed enrollment in a phase 3 trial testing Nyxol in RM patients aged 18 and above and in children aged 12-17 years. If successful, the company expects to submit marketing application for Nyxol to the U.S. Food and Drug Administration in late 2022.

For further details see:

Ocuphire completes enrollment in pediatric patients study of Nyxol eye drops